At the Piper Sandler Symposium, Biogen presented an overview of its lupus franchise, focusing on two lead monoclonal antibodies: litifilimab, targeting BDCA2, and dapirolizumab, targeting CD40L. Management emphasized how these assets address unmet needs in systemic lupus erythematosus.

Biogen shared key efficacy endpoints from ongoing phase 2 trials, including reductions in disease activity scores and corticosteroid tapering success rates. Safety data showed no new adverse signals, supporting transition into larger pivotal studies.

Executives confirmed plans to initiate phase 3 trials for both candidates in mid-2026, outlining site activations and regulatory interactions. The autoimmune franchise remains a core priority, with potential licensing collaborations under active consideration.